Home Archives /C O R R E C T I O N — Skyhawk Therapeutics/ /C O R R E C T I O N — Skyhawk Therapeutics/May 18, 2026 B In the news release, Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule, issued 18-May-2026 by Skyhawk Therapeutics… Login to continue reading Login Sign up for complimentary access Sign Up Now Close posteditor Articles: 21727 Previous Post Family Bonds Foundation Opens Next Round of Nominations Following Record Fundraiser at Travel Leaders Network's EDGE Next Post ‘Song of the Samurai’ Star Yuki Yamada Breaks Down Season 1